Colorectal Cancer

P=N/A, N=750, Not yet recruiting, Changhai Hospital

P2, N=20, Recruiting, Sixth Affiliated Hospital, Sun Yat-sen University | Trial completion date: Feb 2027 --> Jun 2029 | Trial primary completion date: Apr 2026 --> Sep 2026

CCBE1 is an oncogenic driver in colorectal cancer that independently predicts poor survival and functionally enhances tumor cell proliferation, invasion, and M2 macrophage polarization. Targeting CCBE1 may represent a potential therapeutic strategy for colorectal cancer.

Through a comprehensive and systematic search of the best available evidence, the Neoplastic Diseases Task Force developed 20 recommendations on screening and risk factor assessment for 10 specific questions on neoplastic diseases. These recommendations serve as guidance on screening neoplastic diseases at the primary care level.

The findings favored metastatic colorectal carcinoma involving the pancreas in the setting of clinically suspected Lynch syndrome. This case emphasizes the importance of clinicopathologic correlation, cautious interpretation of MMR deficiency, and long-term multidisciplinary surveillance.

We revealed the role of non-histone protein crotonylation in regulating the proliferation and migration of colorectal tumor. Crotonylation inhibited cell proliferation through the crotonylated CDK1 K9 by arresting the cell cycle and inducing apoptosis, and exerts a synergistic effect with the RO-3306 inhibitor.

APE1 protects epithelial cells by inhibiting the accumulation of ROS and oxidative DNA damage induced by intestinal bacteria, including the colibactin produced by E. coli NC101.

Unlike previous reviews, this article critically distinguishes CRC-specific evidence from data extrapolated from other cancers and provides an evidence-level table to guide clinical translation. By integrating clinical, translational, and preclinical evidence, we aim to present a theoretical basis for understanding CRC bone metastasis and for developing targeted therapeutic strategies.

Orthotopic KRAS-mutant xenograft models (LOVO-Luc2 (N = 52) and SW480-Luc2 (N = 52)) were treated with standard-of-care regimens (FOLFOX, bevacizumab, or combination) and longitudinally imaged by CT (N = 104 tumour scans, N = 156 liver scans collected over 4 timepoints)...The most predictive features, GLSZM Gray Level Non-Uniformity, GLRLM Run Length Non-Uniformity Normalized, and GLDM Small Dependence Emphasis, were significantly associated with metastatic burden and survival in a clinical CRC cohort (N = 41), indicating species conservation and translational relevance. Collectively, these data demonstrate that preclinical CT radiomics can identify quantitative imaging features associated with treatment sensitivity and early metastatic progression, supporting translational potential.

It also discusses recent advances in targeting strategies. The review provides insights for developing effective anti-cancer therapies.

NT5E accelerates disease progression by promoting malignant biological behaviors in colorectal cancer and synergistically shaping an immunosuppressive microenvironment with PD-L1. Its overexpression constitutes an independent adverse prognostic factor. This discovery offers novel insights for anti-PD-1/PD-L1 combination immunotherapy.

Metabolic pathway analysis also showed significant differences, with FMD preventing the upregulation of pathways involved in amino acid and nucleotide synthesis, potentially promoting tumour growth. Overall, the findings suggest that periodic FMD may result useful in a multimodal approach for LS management, counteracting gut microbiota alterations.